Head-to-head evidence
Furestem-CD vs remestemcel-L
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: Allogeneic MSC therapy · full Crohn's Disease pipeline
Furestem-CD
Developed by Kangstem Biotech
NCT02000362 · Phase 1/2 · status unknown
This was an uncontrolled, open-label study with no comparator arm and no randomization, so any remission observed cannot be separated from the disease's natural course or a placebo effect; no results have been posted.
remestemcel-L · Ryoncil (approved for pediatric SR-aGvHD)
Marketed by Mesoblast
NCT00482092 · Phase 3 · completed
The study randomly assigned 330 participants and used quadruple masking with matching placebo, with clinical remission measured by CDAI at 28 days as the primary endpoint. However, no trial results or statistical comparison are posted, so the primary endpoint cannot be judged as met or missed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furestem-CD's landscape · remestemcel-L's landscape